Abstract
Hepatitis C virus (HCV) leads to disproportionate morbidity and mortality in the HIV-positive population. A new era of anti-HCV therapeutics is emerging, with many direct antiviral agents and immunomodulating drugs in clinical development. This review discusses HCV treatments in development, with special attention to four agents being studied actively among HIV/HCV-co-infected persons.
MeSH terms
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / chemistry
-
Antiviral Agents / therapeutic use
-
Clinical Trials as Topic
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / therapeutic use
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
HIV Infections / epidemiology
-
Hepacivirus / drug effects*
-
Hepatitis C / complications*
-
Hepatitis C / drug therapy*
-
Hepatitis C / epidemiology
-
Hepatitis C / virology
-
Humans
-
Protease Inhibitors / administration & dosage
-
Protease Inhibitors / chemistry
-
Protease Inhibitors / therapeutic use
-
Treatment Outcome
-
Viral Nonstructural Proteins / antagonists & inhibitors
Substances
-
Antiviral Agents
-
Enzyme Inhibitors
-
Protease Inhibitors
-
Viral Nonstructural Proteins
-
NS-5 protein, hepatitis C virus